Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Home use prothrombin time tests get CLIA waived status under FDA Modernization Act.

This article was originally published in The Gray Sheet

Executive Summary

PRESCRIPTION HOME USE TESTS GET CLIA "WAIVED" STATUS UNDER FDA REFORM BILL, which includes a provision stating that "laboratory examinations and procedures that have been approved" by FDA "for home use" qualify for Clinical Laboratory Improvement Amendments waived status. Although the provisions covers all home use tests, the primary effect of the measure will be ensuring that the Centers for Disease Control and Prevention includes prescription home use tests in the waived category.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel